Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Achillion Pharmaceuticals Stock Is Jumping Today

By Keith Speights - Sep 25, 2019 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are responding enthusiastically to a key FDA designation for the biotech's leading pipeline candidate.

What happened

Shares of Achillion Pharmaceuticals ( ACHN ) were jumping 7.5% higher as of 10:46 a.m. EDT on Wednesday after rising as much as 18% earlier in the day. The nice gain came after the biotech announced that the Food and Drug Administration granted a Breakthrough Therapy designation for danicopan (also known as ACH-4471) in combination with Alexion's Soliris for treating the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH). 

So what

Investors' positive reaction to Achillion's news today reflected their enthusiasm over the potentially smoother pathway to approval that a Breakthrough Therapy designation provides. This designation means that the FDA will essentially hold Achillion's hand through the regulatory approval process by providing guidance on clinical trials. It could also lead to danicopan receiving accelerated approval and priority review by the FDA, which reduces the time required for an approval decision.

Gloved hand holding a test tube

Image source: Getty Images.

Achillion has enjoyed plenty of good news with danicopan so far. At the New Era of Aplastic Anemia and PNH Meeting in May, the biotech reported positive interim results from an ongoing phase 2 clinical study of the drug. In 2017, the FDA granted an orphan drug designation for danicopan in treating PNH, which qualified Achillion for tax credits for clinical testing and other financial incentives.

The company has also had more good news in recent months for another pipeline candidate. In July, it announced positive results from a phase 1 clinical study evaluating experimental oral factor D inhibitor ACH-5228.

Now what

Breakthrough Therapy designation is nice, but it doesn't guarantee that Achillion will ultimately win FDA approval for danicopan. The biotech expects to report top-line data from the phase 2 combination trial of the drug with Soliris in the fourth quarter of 2019. Achillion then hopes to begin a pivotal phase 3 study for danicopan in early 2020.

If this late-stage study goes well, Achillion could have a winner on its hands. But investors in biotech stocks know all too well that clinical testing doesn't always go as smoothly as hoped. It remains to be seen what the future holds for Achillion and its leading pipeline candidate.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
ACHN
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.